| 63.13 Data as of May 17 |  -0.61 / -0.96%Today’s Change | 38.63 Today|||52-Week Range 64.48 | +25.01% Year-to-Date |
| Good News for Roche's Tarceva - Analyst Blog May 16 / Zacks.com | Nektar Posts Wider Loss, Maintains View - Analyst Blog May 15 / Zacks.com |
| Pipeline Progress at Gilead - Analyst Blog May 16 / Zacks.com | Lilly Scraps Oncology Candidate - Analyst Blog May 13 / Zacks.com |
| ASCO '13 Preview: New 'Anti-PD-1' Therapies Shrink Tumors May 15 / TheStreet.com | PDL BioPharma Misses Earnings Ests - Analyst Blog May 13 / Zacks.com |
| ASCO '13 Preview: Roche's Next-Gen Rituxan Steps Up May 15 / TheStreet.com | Narrower-than-Expected Loss at Seattle Genetics - Analyst Blog May 08 / Zacks.com |
| Previous close | 63.74 |
| Today’s open | 62.85 |
| Day’s range | 62.56 - 63.33 |
| Volume | 327,138 |
| Average volume (3 months) | 493,616 |
| Market cap | $177.4B |
| Dividend yield | 2.92% |
| Earnings growth (last year) | -3.76% |
| Earnings growth (this year) | -- |
| Earnings growth (next 5 years) | +8.70% |
| Revenue growth (last year) | +0.76% |
| P/E ratio | -- |
| Price/Sales | 3.51 |
| Price/Book | 13.76 |
| No competitors data available. |
| Last reporting date | October 16, 2012 |
| EPS forecast (this quarter) | $0.00 |
| Annual revenue (last year) | $48.8B |
| Annual profit (last year) | $10.2B |
| Net profit margin | 20.97% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
Chief Executive Officer & Director Severin Schwan, LLD |
Chief Financial & Information Technology Officer Alan Hippe, PhD |
Corporate headquarters Basel, Basel-stadt (basle Town) |
.
